The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The genomic, transcriptomic, and immunologic landscape in solid tumors expressing leukocyte immunoglobulin-like receptor B2 (LILRB2).
 
Sandra Jones
Research Funding - Caris Life Sciences
 
Harris Benjamin Krause
Employment - Caris Life Sciences
 
Jose Noy
Employment - Leon Medical Centers (I)
 
Samuel A. Kareff
Honoraria - Academy for Continued Healthcare Education; HealthCourse, Inc.; Integrity Continuing Education
Speakers' Bureau - i3 Health
Travel, Accommodations, Expenses - FLASCO; IASLC
 
Asaad Trabolsi
No Relationships to Disclose
 
Andrew Elliott
Employment - Caris Life Sciences
 
Alex Patrick Farrell
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
Balazs Halmos
Consulting or Advisory Role - Apollomics; Arcus Biosciences; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Merck; Novartis; Pfizer; Takeda; Turning Point Therapeutics; Veracyte
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Patrick C. Ma
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences
Research Funding - Abbvie (Inst); Apollomics (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Elevation Oncology (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); OncoC4 (Inst); Roche/Genentech (Inst)
 
Wafik S. El-Deiry
Stock and Other Ownership Interests - Chimerix; Oncoceutics; p53-Therapeutics; SMURF-Therapeutics
Consulting or Advisory Role - Rain Therapeutics
Research Funding - Chimerix; D&D Pharmatech
Patents, Royalties, Other Intellectual Property - Patent on therapeutic targeting on hypoxia-inducible factors; Patent on TIC10 (ONC201); Patents pending on the use of small molecules to target mutant p53
Other Relationship - Caris Life Sciences
(OPTIONAL) Uncompensated Relationships - As above
 
Ari M. Vanderwalde
Employment - Caris Life Sciences
Consulting or Advisory Role - Bristol-Myers Squibb; Caris Life Sciences; Compugen; Concerto HealthAI; Elsevier; Inivata
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Replimune (Inst)
 
Milan Radovich
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - LifeOmic
Research Funding - Lilly (Inst)
Patents, Royalties, Other Intellectual Property - Combination therapy for the treatment of TNBC with a PI3K pathway inhibitor that targets PI3KDelta and PI3KGamma (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
George W. Sledge
Leadership - Syndax; Tessa Therapeutics
Stock and Other Ownership Interests - Pionyr; Syndax; Tessa Therapeutics
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; G1 Therapeutics; GRAIL; Synaffix; Syndax; Verseau Therapeutics
Research Funding - Genentech/Roche (Inst); Pfizer (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Tessa Therapeutics; Verseau Therapeutics
 
Gilberto Lopes
Stock and Other Ownership Interests - Lucence Diagnostics; Xilis
Honoraria - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Janssen; Merck
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); E.R. Squibb Sons, LLC; EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst); Xilis
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Celgene; E.R. Squibb Sons, LLC; Ipsen; Janssen; Merck; Pfizer; Pharmacyclics; Seagen; Seagen
Other Relationship - Mirati Therapeutics